T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis
Sponsor
Stanford University (Other)
Overall Status
Completed
CT.gov ID
NCT01078337
Collaborator
(none)
15
1
59
0.3
Study Details
Study Description
Brief Summary
To determine if MRD (minimal residual disease) can be found in the blood (only) as opposed to bone marrow in children with ALL (acute lymphoblastic leukemia).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
15 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
T-cell MRD Evaluation Using Flow Cytometric Analysis
Study Start Date
:
Nov 1, 2002
Actual Primary Completion Date
:
Oct 1, 2007
Actual Study Completion Date
:
Oct 1, 2007
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- Children with newly diagnosed T-cell ALL
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Stanford University School of Medicine | Stanford | California | United States | 94305 |
Sponsors and Collaborators
- Stanford University
Investigators
- Principal Investigator: Gary V Dahl, Stanford University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT01078337
Other Study ID Numbers:
- SU-11022007-790
- PEDSALL0001
First Posted:
Mar 2, 2010
Last Update Posted:
Mar 2, 2010
Last Verified:
Feb 1, 2010